Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database

Rippel, Noa; Tremblay, Douglas; Zubizarreta, Nicole; Podoltsev, Nikolai A.; Gotlib, Jason; Heaney, Mark L.; Kuykendall, Andrew; Shammo, Jamile M.; Fleischman, Angela G.; Kremyanskaya, Marina; Hoffman, Ronald; Mesa, Ruben A.; Yacoub, Abdulraheem; Mascarenhas, John

doi:10.1016/j.leukres.2022.106903

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A target of <45% is associated with improved morbidity and mortality in PV subjects [ 4 ]. Phlebotomy is used in conjunction with hydroxyurea chemotherapy and anagrelide medicine, preventing platelets from maturing [ 4 , 8 ]. Antiplatelet therapy with low-dose aspirin is known to cause an overall reduction in mortality and thrombotic events [ 9 , 10 ].…”

Section: Discussionmentioning

confidence: 99%

Polycythemia Vera Presenting As Acute Non-hemorrhagic Infarction and Chronic Bleed: Deception Between the Lines

Kotak,

Malali,

Kumar

et al. 2024

Cureus

View full text Add to dashboard Cite

Patients with polycythemia vera (PV) develop various complications due to hyper-viscous blood, causing events such as ischemic stroke. There are other associated complications due to the dysfunction of platelet activity, causing hemorrhages. In our unusual case, we present a patient who came to the OPD complaining of slurring speech. An MRI was done and was suggestive of acute lacunar infarcts with changes in chronic bleed. CBC and hematocrit were consistent for PV, with the genetic marker JAK2 being positive.

show abstract